New targeted therapy trial offers hope for hard-to-treat cancers with specific genetic flaw
NCT ID NCT04439123
Summary
This study is testing whether the drug AZD5363 can help control advanced cancers that have a specific genetic change called an AKT mutation. The trial includes 35 patients with various cancers (solid tumors, lymphoma, or myeloma) that have stopped responding to standard treatments. Researchers want to see if blocking the AKT protein with this oral medication can shrink tumors or stop their growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.